AP NEWS

Acticor Biotech Confirms Simbec-Orion to Make Its First in Patient Study in Acute Ischemic Stroke

June 14, 2018

PARIS--(BUSINESS WIRE)--Jun 14, 2018--Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, as part of the development of its first drug candidate ACT017 who has just successfully completed a phase 1 study in the healthy volunteer, confided to Simbec-Orion carrying out his first in patient study, in acute ischemic stroke.

This phase 2 study, which will include a first group of 100 patients in 8 European countries, must be used to confirm the patient’s safety of use while trying to provide evidence of vascular and neurological efficacy.

This randomized study will be conducted in expert centers that can accommodate this type of patient 24 hours a day, 7 days a week, giving them the best standard of care, namely intravenous thrombolysis and thrombectomy.

It is precisely this standard of care that will be used as a comparison with ACT017, which will be injected as a 6-hour infusion in addition to the standard of care.

The study will start in the autumn and the submission of the protocol to the competent authorities of the countries concerned will be made starting in June.

Dr. Gilles Avenard, CEO of Acticor Biotech commented on this decision: “This study is key for us because it initiates all the clinical development of our drug candidate in a severe and frequent indication in dire need of new treatments. It was essential that it be conducted with the best experts and European centers we trust. We selected Simbec-Orion following a very wide consultation based on their international experience in this indication. Our goal is to confirm the interest of inhibition of platelet glycoprotein GPVI in patients in acute ischemic phase. ”

Fabrice Chartier, Group Chief Operating Officer of Simbec-Orion, commented: “We are very honored to have been chosen by Acticor Biotech for this essential study. We are very confident in the professionalism of the R & D team of this company and also in the value of this very innovative project. This is an important challenge too, as such studies are highly qualified and require constant attention. It is in the spirit of Simbec-Orion to seek to meet such challenges and be a partner of choice for innovation companies. ”

About Simbec -Orion - http://www.simbecorioncro.com/

About ACT017, the Therapeutic Candidate - https://acticor-biotech.com/technology/

About Acticor Biotech - https://acticor-biotech.com/

View source version on businesswire.com:https://www.businesswire.com/news/home/20180614005644/en/

CONTACT: Acticor Biotech:

Gilles Avenard

Chief Executive Officer

gilles.avenard@acticor-biotech.com

or

Media – NewCap:

Annie-Florence Loyer

+33(0) 1 44 71 00 12 / +33(0) 6 88 20 35 59

afloyer@newcap.fr

KEYWORD: EUROPE FRANCE

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CARDIOLOGY CLINICAL TRIALS HOSPITALS PHARMACEUTICAL

SOURCE: Acticor Biotech

Copyright Business Wire 2018.

PUB: 06/14/2018 09:53 AM/DISC: 06/14/2018 09:53 AM

http://www.businesswire.com/news/home/20180614005644/en

AP RADIO
Update hourly